Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655000 | 0.80 | HSD11B1 (0.36) | GPR119HSD11B1MAOAMAOBMEN1 | |
| SCHEMBL7602702 | 0.78 | KDM4E (0.35) | GPR119HSD11B1MAOAMAOBMEN1 | |
| SCHEMBL443319 | 0.78 | HSD11B1 (0.38) | NOTUMGPR119HSD11B1MAOAMAOB | |
| SCHEMBL15110040 | 0.78 | HSD11B1 (0.35) | GPR119HSD11B1MAOAMAOBMEN1 | |
| SCHEMBL23791454 | 0.78 | HSD11B1 (0.35) | GPR119HSD11B1MAOAMAOBMEN1 | |
| SCHEMBL10094578 | 0.77 | NPC1 (0.41) | GPR119HSD11B1MAOAMAOBMEN1 | |
| SCHEMBL15932001 | 0.75 | HSD11B1 (0.36) | GPR119HSD11B1MEN1KMT2A | |
| SCHEMBL1771274 | 0.75 | HSD11B1 (0.34) | GPR119HSD11B1 | |
| SCHEMBL10094574 | 0.75 | HSD11B1 (0.45) | GPR119HSD11B1 | |
| SCHEMBL10094575 | 0.75 | POLB (0.38) | GPR119HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9820954-B2 | Quantitative peri-orbital application of ophthalmology drugs | JENIVISION INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820954-B2 | Quantitative peri-orbital application of ophthalmology drugs | JENIVISION INC. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017031137-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. | 2017-02-23 | — | — | US | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2523954-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD Oss B.V. (NL) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | PTGIR, QDPR, PDE3A | NOTUM 3226/4885GPR119 1798/4885HSD11B1 1402/4885 |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSZ | NOTUM 1383/4885GPR119 1194/4885HSD11B1 3066/4885 |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | HRH2, UGT1A3, UGT1A1 | NOTUM 4629/4885GPR119 470/4885HSD11B1 1324/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | NOTUM 2760/4885GPR119 188/4885HSD11B1 432/4885 |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | BRS3, BRSK1, BRSK2 | NOTUM 2270/4885GPR119 4/4885HSD11B1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.